- Home
- EPSN vs XFOR Comparison
EPSN vs XFOR Comparison
Compare EPSN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- XFOR
- Stock Information
- Founded
- EPSN 2005
- XFOR 2014
- Country
- EPSN Canada
- XFOR United States
- Employees
- EPSN N/A
- XFOR N/A
- Industry
- EPSN Oil & Gas Production
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPSN Energy
- XFOR Health Care
- Exchange
- EPSN Nasdaq
- XFOR Nasdaq
- Market Cap
- EPSN 124.0M
- XFOR 84.3M
- IPO Year
- EPSN N/A
- XFOR N/A
- Fundamental
- Price
- EPSN $5.32
- XFOR $3.21
- Analyst Decision
- EPSN Strong Buy
- XFOR Strong Buy
- Analyst Count
- EPSN 1
- XFOR 3
- Target Price
- EPSN $7.00
- XFOR $34.17
- AVG Volume (30 Days)
- EPSN 108.8K
- XFOR 1.5M
- Earning Date
- EPSN 11-05-2025
- XFOR 11-12-2025
- Dividend Yield
- EPSN 4.68%
- XFOR N/A
- EPS Growth
- EPSN N/A
- XFOR N/A
- EPS
- EPSN 0.23
- XFOR N/A
- Revenue
- EPSN $44,016,087.00
- XFOR $32,774,000.00
- Revenue This Year
- EPSN $41.35
- XFOR $1,313.84
- Revenue Next Year
- EPSN N/A
- XFOR N/A
- P/E Ratio
- EPSN $22.99
- XFOR N/A
- Revenue Growth
- EPSN 45.90
- XFOR 5721.31
- 52 Week Low
- EPSN $4.95
- XFOR $1.35
- 52 Week High
- EPSN $8.50
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- EPSN 32.82
- XFOR 51.32
- Support Level
- EPSN $5.28
- XFOR $3.08
- Resistance Level
- EPSN $5.59
- XFOR $3.79
- Average True Range (ATR)
- EPSN 0.17
- XFOR 0.40
- MACD
- EPSN -0.02
- XFOR -0.11
- Stochastic Oscillator
- EPSN 5.63
- XFOR 16.92
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.